Pitfalls of therapies targeting the nitric oxide signaling pathway in heart failure with preserved…

The University of Virginia awarded contract A207_PO-0446151-V3 to Wolters Kluwer Health Inc on June 13, 2026. Wolters Kluwer Health Inc, the prime contractor, is delivering specialized medical literature and research content focused on cardiovascular therapeutics to the University of Virginia in Virginia. The specific deliverable identified in the contract documentation pertains to clinical research materials addressing therapeutic approaches targeting the nitric oxide signaling pathway in the context of heart failure with preserved ejection fraction.

The contract structure indicates a unit-based delivery model with the materials being delivered to the designated buyer at the University of Virginia. While specific contract valuation, period of performance duration, and county-level information are not detailed in the available documentation, the award represents an acquisition of specialized medical reference and research materials by a major academic medical institution from an established healthcare information and publishing provider. The contract mechanics suggest a transactional purchase order arrangement rather than an ongoing service engagement.